|BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14|
A live webcast of the presentation will be available on BioLineRx's website. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.
Investors or potential partners attending the conference who wish to meet with BioLineRx management should contact the BIO Partnering Team at firstname.lastname@example.org.
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in
BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML and is in the midst of a Phase 2b study as an AML consolidation treatment and a Phase 2 study in stem cell mobilization for allogeneic transplantation; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with
For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's
Contacts for BioLineRx: